Crestchem Ltd
Incorporated in 1991, Crestchem Ltd is in
the field of processing, manufacturing, and trading and marketing, of specialty chemical
ingredients,[1]
- Market Cap ₹ 37.8 Cr.
- Current Price ₹ 126
- High / Low ₹ 155 / 73.0
- Stock P/E 14.0
- Book Value ₹ 33.0
- Dividend Yield 1.19 %
- ROCE %
- ROE 27.4 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.81 times its book value
- Promoter holding is low: 29.8%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 29.42 | |
| 26.24 | |
| Operating Profit | 3.18 |
| OPM % | 10.81% |
| 0.66 | |
| Interest | 0.01 |
| Depreciation | 0.07 |
| Profit before tax | 3.76 |
| Tax % | 27.93% |
| 2.71 | |
| EPS in Rs | 9.03 |
| Dividend Payout % | 16.61% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 21% |
| 3 Years: | 27% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 27% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | 3.00 |
| Reserves | 6.89 |
| 0.00 | |
| 6.35 | |
| Total Liabilities | 16.24 |
| 0.19 | |
| CWIP | 0.00 |
| Investments | 0.00 |
| 16.05 | |
| Total Assets | 16.24 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 3.59 | |
| -3.75 | |
| -0.17 | |
| Net Cash Flow | -0.33 |
| Free Cash Flow | 3.59 |
| CFO/OP | 129% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | 44.79 |
| Inventory Days | 0.00 |
| Days Payable | |
| Cash Conversion Cycle | 44.79 |
| Working Capital Days | -12.90 |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of major customers (>=10% of total revenue) count ・Standalone data |
|
||||||||
| Revenue from single largest customer as % of total revenue % ・Standalone data |
|||||||||
| Number of permanent employees on rolls count ・Standalone data |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Dear Sir/Madam, As per Regulation 47 to the SEBI (LODR) Regulations, 2015 (''Listing Regulations''), as amended, please find enclosed herewith ....
-
Board Meeting Outcome for Submission Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30,
2026 Regulation 30 & 33 And Part A Of Schedule Ill Of The SEBI (Listing Obligations And Disclosure
Requirements) Regulations, 2015
- Board approved unaudited standalone and consolidated Q1 FY2026 results on August 12, 2026.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- 34th AGM held on August 6, 2026 via VC; 42 members attended, voting completed.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday At 04:30 Pm (Noon) , August 12, 2026
- Board meets August 12, 2026 for Q1 results and notes BSE fine for late cash flow submission.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2][3]
CL specializes in manufacturing, processing, marketing, and exporting nutraceutical ingredients used in health food, personal care, and specialty chemicals. Its key products, Caprylic/Capric Triglycerides in oil and powder form, along with downstream derivatives, also have industrial applications.